Agenus Combination Therapy Shows Promise in Challenging Colorectal Cancer Subset
Event summary
- Agenus will present preliminary data from the BBoPCO study at the AACR Annual Meeting 2026 (April 18-23).
- The BBoPCO study evaluates botensilimab (BOT) and balstilimab (BAL) in first-line treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
- The study focuses on a patient population (MSS mCRC without liver, bone, or brain metastases) historically resistant to immunotherapy.
- Approximately 1,200 patients have been treated with botensilimab and/or balstilimab across Phase 1 and Phase 2 trials.
The big picture
MSS colorectal cancer represents approximately 95% of metastatic cases and has historically been resistant to immunotherapy, creating a significant unmet medical need. Agenus' approach of combining CTLA-4 and PD-1 blockade aims to overcome this resistance, but success hinges on demonstrating efficacy in this challenging patient population. The BBoPCO study represents a strategic shift towards earlier immunotherapy adoption, potentially reducing reliance on toxic chemotherapy regimens.
What we're watching
- Clinical Efficacy
- The AACR presentation’s data will be critical in determining if the BOT+BAL combination demonstrates meaningful clinical benefit in MSS mCRC, a population with limited treatment options.
- Regulatory Pathway
- Success in this trial could accelerate Agenus’ efforts to secure accelerated approval or priority review for the combination therapy, but will depend on the strength of the data presented.
- Competitive Landscape
- The results will be closely scrutinized by competitors developing other immunotherapy combinations for colorectal cancer, potentially influencing their development strategies and clinical trial designs.
Related topics